vs
爵士制药（JAZZ）与Rivian Automotive, Inc.（RIVN）财务数据对比。点击上方公司名可切换其他公司
Rivian Automotive, Inc.的季度营收约是爵士制药的1.1倍（$1.3B vs $1.2B），爵士制药净利率更高（17.0% vs -63.1%，领先80.0%），爵士制药同比增速更快（10.1% vs -25.8%），爵士制药自由现金流更多（$345.8M vs $-1.1B），过去两年爵士制药的营收复合增速更高（15.2% vs 3.3%）
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
JAZZ vs RIVN — 直观对比
营收规模更大
RIVN
是对方的1.1倍
$1.2B
营收增速更快
JAZZ
高出35.9%
-25.8%
净利率更高
JAZZ
高出80.0%
-63.1%
自由现金流更多
JAZZ
多$1.5B
$-1.1B
两年增速更快
JAZZ
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.3B |
| 净利润 | $203.5M | $-811.0M |
| 毛利率 | — | 9.3% |
| 营业利润率 | 21.2% | -64.8% |
| 净利率 | 17.0% | -63.1% |
| 营收同比 | 10.1% | -25.8% |
| 净利润同比 | 6.5% | -9.0% |
| 每股收益（稀释后） | $3.34 | $-0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAZZRIVN
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $1.1B | $1.6B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $897.8M | $1.2B | ||
| Q4 24 | $1.1B | $1.7B | ||
| Q3 24 | $1.1B | $874.0M | ||
| Q2 24 | $1.0B | $1.2B | ||
| Q1 24 | $902.0M | $1.2B |
净利润JAZZRIVN
| Q4 25 | $203.5M | $-811.0M | ||
| Q3 25 | $251.4M | $-1.2B | ||
| Q2 25 | $-718.5M | $-1.1B | ||
| Q1 25 | $-92.5M | $-545.0M | ||
| Q4 24 | $191.1M | $-744.0M | ||
| Q3 24 | $215.1M | $-1.1B | ||
| Q2 24 | $168.6M | $-1.5B | ||
| Q1 24 | $-14.6M | $-1.4B |
毛利率JAZZRIVN
| Q4 25 | — | 9.3% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | -15.8% | ||
| Q1 25 | — | 16.6% | ||
| Q4 24 | — | 9.8% | ||
| Q3 24 | — | -44.9% | ||
| Q2 24 | — | -38.9% | ||
| Q1 24 | — | -43.8% |
营业利润率JAZZRIVN
| Q4 25 | 21.2% | -64.8% | ||
| Q3 25 | 5.1% | -63.1% | ||
| Q2 25 | -65.6% | -85.5% | ||
| Q1 25 | -6.2% | -52.8% | ||
| Q4 24 | 17.5% | -38.1% | ||
| Q3 24 | 24.7% | -133.8% | ||
| Q2 24 | 19.5% | -118.7% | ||
| Q1 24 | 7.3% | -123.3% |
净利率JAZZRIVN
| Q4 25 | 17.0% | -63.1% | ||
| Q3 25 | 22.3% | -75.3% | ||
| Q2 25 | -68.7% | -85.7% | ||
| Q1 25 | -10.3% | -44.0% | ||
| Q4 24 | 17.6% | -42.9% | ||
| Q3 24 | 20.4% | -125.9% | ||
| Q2 24 | 16.5% | -125.8% | ||
| Q1 24 | -1.6% | -120.1% |
每股收益（稀释后）JAZZRIVN
| Q4 25 | $3.34 | $-0.66 | ||
| Q3 25 | $4.08 | $-0.96 | ||
| Q2 25 | $-11.74 | $-0.97 | ||
| Q1 25 | $-1.52 | $-0.48 | ||
| Q4 24 | $2.97 | $-0.67 | ||
| Q3 24 | $3.42 | $-1.08 | ||
| Q2 24 | $2.49 | $-1.46 | ||
| Q1 24 | $-0.23 | $-1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $6.1B |
| 总债务越低越好 | $5.4B | — |
| 股东权益账面价值 | $4.3B | $4.6B |
| 总资产 | $11.7B | $14.9B |
| 负债/权益比越低杠杆越低 | 1.24× | — |
8季度趋势，按日历期对齐
现金及短期投资JAZZRIVN
| Q4 25 | $1.4B | $6.1B | ||
| Q3 25 | $1.3B | $7.1B | ||
| Q2 25 | $1.2B | $7.5B | ||
| Q1 25 | $1.9B | $7.2B | ||
| Q4 24 | $2.4B | $7.7B | ||
| Q3 24 | $2.2B | $6.7B | ||
| Q2 24 | $1.4B | $7.9B | ||
| Q1 24 | $1.4B | $7.9B |
总债务JAZZRIVN
| Q4 25 | $5.4B | — | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | $5.5B | ||
| Q1 24 | $5.7B | $4.4B |
股东权益JAZZRIVN
| Q4 25 | $4.3B | $4.6B | ||
| Q3 25 | $4.0B | $5.1B | ||
| Q2 25 | $3.7B | $6.1B | ||
| Q1 25 | $4.2B | $6.2B | ||
| Q4 24 | $4.1B | $6.6B | ||
| Q3 24 | $4.2B | $5.9B | ||
| Q2 24 | $3.8B | $6.8B | ||
| Q1 24 | $3.7B | $8.1B |
总资产JAZZRIVN
| Q4 25 | $11.7B | $14.9B | ||
| Q3 25 | $11.4B | $15.2B | ||
| Q2 25 | $10.9B | $15.6B | ||
| Q1 25 | $11.5B | $15.5B | ||
| Q4 24 | $12.0B | $15.4B | ||
| Q3 24 | $12.3B | $14.3B | ||
| Q2 24 | $11.4B | $15.4B | ||
| Q1 24 | $11.3B | $15.7B |
负债/权益比JAZZRIVN
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | 0.81× | ||
| Q1 24 | 1.54× | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $362.5M | $-681.0M |
| 自由现金流经营现金流 - 资本支出 | $345.8M | $-1.1B |
| 自由现金流率自由现金流/营收 | 28.9% | -89.0% |
| 资本支出强度资本支出/营收 | 1.4% | 36.0% |
| 现金转化率经营现金流/净利润 | 1.78× | — |
| 过去12个月自由现金流最近4个季度 | $1.3B | $-2.5B |
8季度趋势，按日历期对齐
经营现金流JAZZRIVN
| Q4 25 | $362.5M | $-681.0M | ||
| Q3 25 | $474.6M | $26.0M | ||
| Q2 25 | $88.9M | $64.0M | ||
| Q1 25 | $429.8M | $-188.0M | ||
| Q4 24 | $398.6M | $1.2B | ||
| Q3 24 | $398.7M | $-876.0M | ||
| Q2 24 | $331.4M | $-754.0M | ||
| Q1 24 | $267.2M | $-1.3B |
自由现金流JAZZRIVN
| Q4 25 | $345.8M | $-1.1B | ||
| Q3 25 | $459.4M | $-421.0M | ||
| Q2 25 | $75.9M | $-398.0M | ||
| Q1 25 | $415.9M | $-526.0M | ||
| Q4 24 | $385.3M | $856.0M | ||
| Q3 24 | $388.0M | $-1.2B | ||
| Q2 24 | $324.3M | $-1.0B | ||
| Q1 24 | $260.3M | $-1.5B |
自由现金流率JAZZRIVN
| Q4 25 | 28.9% | -89.0% | ||
| Q3 25 | 40.8% | -27.0% | ||
| Q2 25 | 7.3% | -30.5% | ||
| Q1 25 | 46.3% | -42.4% | ||
| Q4 24 | 35.4% | 49.4% | ||
| Q3 24 | 36.8% | -131.9% | ||
| Q2 24 | 31.7% | -89.6% | ||
| Q1 24 | 28.9% | -126.5% |
资本支出强度JAZZRIVN
| Q4 25 | 1.4% | 36.0% | ||
| Q3 25 | 1.3% | 28.7% | ||
| Q2 25 | 1.2% | 35.5% | ||
| Q1 25 | 1.5% | 27.3% | ||
| Q4 24 | 1.2% | 18.9% | ||
| Q3 24 | 1.0% | 31.7% | ||
| Q2 24 | 0.7% | 24.4% | ||
| Q1 24 | 0.8% | 21.1% |
现金转化率JAZZRIVN
| Q4 25 | 1.78× | — | ||
| Q3 25 | 1.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.97× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
